165 related articles for article (PubMed ID: 37543824)
1. Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report.
Li H; Mu F; Zou B; Wang L
Medicine (Baltimore); 2023 Aug; 102(31):e34432. PubMed ID: 37543824
[TBL] [Abstract][Full Text] [Related]
2. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y
Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096
[TBL] [Abstract][Full Text] [Related]
3. Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.
Gkiozos I; Kopitopoulou A; Kalkanis A; Vamvakaris IN; Judson MA; Syrigos KN
J Thorac Oncol; 2018 Aug; 13(8):1076-1082. PubMed ID: 29763666
[TBL] [Abstract][Full Text] [Related]
4. Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature.
Yan J; Ma N; Qiao WL; Liu KQ; Liu DW; Wang Y; Qiao TT; Hao XQ; Zheng MD
Ann Transl Med; 2022 Dec; 10(24):1411. PubMed ID: 36660611
[TBL] [Abstract][Full Text] [Related]
5. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
7. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract][Full Text] [Related]
8. Case Report and Review of 7 Similar Cases in the Literature: Cutaneous Sarcoidosis as Side Effect of Pembrolizumab Plus Chemotherapy in Stage IV Squamous Cell Carcinoma of Lung.
Trilleras-Gomez AP; Hull KJ; Drew DZ
J Immunother; 2021 Feb-Mar 01; 44(2):90-94. PubMed ID: 33298795
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report.
Hong G; Zhao H; Yin Y; Shen H; Zeng Z; Yang J; Zhang L
Front Immunol; 2023; 14():1253463. PubMed ID: 37920461
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment.
Sirgi Y; Krochmal R; Fleury CM; Holmes M; Dewitt CA; Cardis M; Kim C
Clin Lung Cancer; 2022 Sep; 23(6):542-546. PubMed ID: 35701321
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study.
Cabanié C; Ammari S; Hans S; Pobel C; Laparra A; Danlos FX; Chanson N; Dolidon S; Seban R; Voisin AL; Pautier P; Romano-Martin P; Even C; Baldini C; Besse B; Albiges L; Boutros C; Routier E; Balleyguier C; De Montpreville VT; Champiat S; Massard C; Robert C; Marabelle A; Mateus C; Lambotte O; Le Pavec J; Michot JM
Eur J Cancer; 2021 Oct; 156():46-59. PubMed ID: 34425404
[TBL] [Abstract][Full Text] [Related]
12. Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital.
Torres-Jiménez J; Esteban-Villarrubia J; García-Abellás P; Cortés-Salgado A; Soria-Rivas A; Gajate-Borau P; Olmedo-García ME; Corral-de la Fuente E; Lage-Alfranca Y; Gómez-Rueda A; Benito-Berlinches A; Gorospe-Sarasua L; Garrido-López P
Clin Transl Oncol; 2021 Jul; 23(7):1474-1480. PubMed ID: 33433837
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.
Zhang Z; Ye J; Li H; Gu D; Du M; Ai D; Chen W; Fang Y; Xu X; Bai C; Zhao K; Zhou G
Front Immunol; 2022; 13():1031171. PubMed ID: 36311804
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report.
Wen YP; Xiao HW; Yin JH; Guo HR; Shan MJ; Shen LP; Liu LS
Medicine (Baltimore); 2022 Dec; 101(48):e32076. PubMed ID: 36482651
[TBL] [Abstract][Full Text] [Related]
15. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
Front Immunol; 2022; 13():931429. PubMed ID: 36248782
[TBL] [Abstract][Full Text] [Related]
16. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
[TBL] [Abstract][Full Text] [Related]
19. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
20. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis.
Kim ST; Pundole X; Dadu R; Lambotte O; Ramos-Casals M; Suarez-Almazor ME
Immunotherapy; 2021 Apr; 13(6):465-475. PubMed ID: 33641345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
